Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a […]
Drugs targeting HER2 have shown excellent clinical efficacy over the 20 years, achieving one milestone after another in the field of cancer therapeutics. This article mainly introduces the development history […]
Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]
1. Respiratory system 1.1. Lung cancer Drug Name Trade name CAS Target Description Approved Status Gefitinib lressa 184475-35-2 EGFR Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both […]
Introduction of IAP Apoptosis, or programmed death, is a natural cell cycle process designed to eliminate unwanted or damaged cells from the body. In healthy tissues, there is a good […]
Proteasome is the main pathway by which misfolded proteins and other proteins are proteolyzed during protein synthesis. It is found in all eukaryotic cells, archaea and some bacteria and is […]
Breast cancer (BC) is a serious threat to women’s health of malignant tumors. According to the latest national cancer statistics released by the National Cancer Center, breast cancer is still […]
P53 is a well-known human anticancer protein, known as the guardian of the human genome. Wild-type p53 (WTp53) are widely found in nature. Recently, scientists from the University of California found […]
Introduction P53 tumor suppressor gene is a kind of gene that inhibits cells from transforming into cancer cells in living organisms. There are oncogene and tumor suppressor gene in the […]
This article takes stock of the latest clinical development pipeline for lung and liver cancer. We calculated clinical trial data for clinical phase Ⅰ, and phase Ⅱ and phase Ⅲ […]
- 2 of 4
- « Previous
- 1
- 2
- 3
- 4
- Next »